Long-term strategy for the treatment of gastro-oesophageal reflux disease

Keyphrases

• Long-term Strategy 100%
• Gastroesophageal Reflux Disease 100%
• Esophagitis 100%
• Natural History 50%
• Omeprazole 50%
• Healing 33%
• Reflux Esophagitis 33%
• Columnar Metaplasia 33%
• Tumor 16%
• Long-term Treatment 16%
• Disease Severity 16%
• Placebo 16%
• Recurring 16%
• Moderate to Severe 16%
• Conservative Treatment 16%
• Precancerous Lesions 16%
• Carcinoma 16%
• Epithelium 16%
• Standard Current 16%
• Mild Disease 16%
• Relapse Prevention 16%
• Advanced Tumor 16%
• Medical Therapy 16%
• Relapse Rate 16%
• Surgical Therapy 16%
• Reflux 16%
• Lifestyle Modification 16%
• Postoperative Morbidity 16%
• Complication Prevention 16%
• H2-receptor Antagonists 16%
• Cisapride 16%
• Premature Discontinuation 16%
• Reflux Disease 16%
• Fundoplication 16%
• Nissen Fundoplication 16%
• Healing Rate 16%
• Antireflux 16%
• Clearance Time 16%
• Columnar Epithelium 16%
• Severe Dysplasia 16%
• Acid Suppression 16%
• Surgical Failure 16%

Medicine and Dentistry

• Gastroesophageal Reflux 100%
• Esophagitis 100%
• Reflux 50%
• Omeprazole 50%
• Diseases 50%
• Neoplasm 33%
• Metaplasia 33%
• Nissen Fundoplication 33%
• Reflux Esophagitis 33%
• Combination Therapy 16%
• Precancerous Condition 16%
• Recurrence Risk 16%
• Sequela 16%
• Receptor Antagonist 16%
• Carcinoma 16%
• Conservative Treatment 16%
• Lifestyle Modification 16%
• Dysplasia 16%
• Columnar Epithelium 16%
• Placebo 16%
• Histamine H2 Receptor 16%
• Cisapride 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Gastroesophageal Reflux 100%
• Esophagitis 100%
• Omeprazole 50%
• Diseases 50%
• Metaplasia 33%
• Reflux Esophagitis 33%
• Neoplasm 33%
• Cisapride 16%
• Syndrome 16%
• Placebo 16%
• Recurrence Risk 16%
• Precancer 16%
• Dysplasia 16%
• Histamine H2 Receptor Antagonist 16%
• Combination Therapy 16%
• Carcinoma 16%